Table 3.

Univariate and multivariate analyses of factors associated with bFFF

				bFFF
				Univariate analysis	Multivariate analysis
		Number of patients	7-year bFFF (%)	p-value	p-value	Hazard ratio	95% CI
Age (years)	< 71	40	78.8	0.349	–
	≥ 71	32	67.0
iPSA (ng/ml)	≤ 20	51	86.6	< 0.001	0.024	0.234	0.067–0.825
	> 20	21	48.6
Grade group	≤ 3	40	66.0	0.023	0.767	1.254	0.280–5.607
	≥ 4	32	85.4
Clinical T stage	2	54	70.1	0.278	–
	3a	18	88.5
PLND	+	43	70.2	0.544	–
	–	29	76.5
BED (Gy)	< 270.3	34	68.3	0.192	–
	≥ 270.3	38	79.0

bFFF biochemical freedom from failure, iPSA initial prostate-specific antigen, PLND pelvic lymph node dissection, BED biologically effective dose